Prevalence and Determinants of Vaccine Hesitancy and Vaccines Recommendation Discrepancies among General Practitioners in French-Speaking Parts of Belgium
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Data Collection
2.3. Immunization Discrepancies between Family and Patients of General Practitioners
2.4. Statistical Analysis
3. Results
3.1. Characteristics of the Study Population
3.2. Definition and Prevalence of Vaccine Hesitancy
3.3. Determinants of Moderate to High Vaccine Hesitancy
3.4. Discrepancies between General Practitioners Family Immunization Practice and Patient’s Immunization Recommendations
4. Discussion
4.1. Prevalence and Degree of Vaccine Hesitancy
4.2. Determinants of Moderate to High Vaccine Hesitancy
4.3. Vaccine Discordance of General Practitioners between the Vaccination of Their Children and Their Professional Recommendations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bloom, D.E.; Fan, V.Y.; Sevilla, J.P. The broad socioeconomic benefits of vaccination. Sci. Transl. Med. 2018, 10, eaaj2345. [Google Scholar] [CrossRef] [PubMed]
- Conseil Supérieur de la Santé (CSS). CSS 9141—Calendrier Vaccinal de Base Recommandé Par Le CSS; Conseil Supérieur de la Santé: Brussel, Belgium, 2019. [Google Scholar]
- Wyndham-Thomas, C.; Grammens, T.; Litzroth, A.; Sizaire, V.; Boon, N.; Muyldermans, G.; Lernout, T. Maladies infectieuses à prévention vaccinale. Synthèse annuelle 2017. Bruxelles, Belgique: Sciensano; 2019. Numéro de rapport: D/2019/14.440/22. Available online: https://www.sciensano.be/sites/default/files/maladies_infectieuses_pediatriques_a_prevention_vaccinale._synthese_annuelle_2017.pdf (accessed on 10 July 2021).
- Grammens, T.; Schirvel, C.; Leenen, S.; Shodu, N.; Hutse, V.; Da Costa, E.M.; Sabbe, M. Ongoing measles outbreak in Wallonia, Belgium, December 2016 to March 2017: Characteristics and challenges. Eurosurveillance 2017, 22. [Google Scholar] [CrossRef] [PubMed]
- Cornelissen, L.; Grammens, T.; Leenen, S.; Schirvel, C.; Hutse, V.; Demeester, R.; Swennen, B.; Asikainen, T.; Wyndham-Thomas, C. High number of hospitalisations and non-classical presentations: Lessons learned from a measles outbreak in 2017, Belgium. Epidemiol. Infect. 2020, 148, e35. [Google Scholar] [CrossRef] [Green Version]
- Gostin, L.; Hodge, J.G.; Bloom, B.R.; El-Mohandes, A.; Fielding, J.; Hotez, P.; Kurth, A.; Larson, H.J.; Orenstein, W.; Rabin, K.; et al. The public health crisis of underimmunisation: A global plan of action. Lancet Infect. Dis. 2020, 20, e11–e16. [Google Scholar] [CrossRef]
- MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [Google Scholar] [CrossRef] [PubMed]
- Lane, S.; MacDonald, N.E.; Marti, M.; Dumolard, L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015–2017. Vaccine 2018, 36, 3861–3867. [Google Scholar] [CrossRef]
- Larson, H.J.; De Figueiredo, A.; Xiahong, Z.; Schulz, W.S.; Verger, P.; Johnston, I.; Cook, A.R.; Jones, N.S. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine 2016, 12, 295–301. [Google Scholar] [CrossRef] [Green Version]
- Karafillakis, E.; Larson, H.J. The paradox of vaccine hesitancy among healthcare professionals. Clin. Microbiol. Infect. 2018, 24, 799–800. [Google Scholar] [CrossRef] [Green Version]
- Verger, P.; Collange, F.; Fressard, L.; Bocquier, A.; Gautier, A.; Pulcini, C.; Raude, J.; Peretti-Watel, P. Prevalence and correlates of vaccine hesitancy among general practitioners: A cross-sectional telephone survey in France, April to July 2014. Eurosurveillance 2016, 21, 30406. [Google Scholar] [CrossRef]
- Karafillakis, E.; Dinca, I.; Apfel, F.; Cecconi, S.; Wűrz, A.; Takacs, J.; Suk, J.; Celentano, L.P.; Kramarz, P.; Larson, H.J. Vaccine hesitancy among healthcare workers in Europe: A qualitative study. Vaccine 2016, 34, 5013–5020. [Google Scholar] [CrossRef]
- Harrison, N.; Poeppl, W.; Miksch, M.; Machold, K.; Kiener, H.; Aletaha, D.; Smolen, J.S.; Forstner, C.; Burgmann, H.; Lagler, H. Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. Vaccine 2018, 36, 4875–4879. [Google Scholar] [CrossRef] [PubMed]
- Killian, M.; Detoc, M.; Berthelot, P.; Charles, R.; Gagneux-Brunon, A.; Lucht, F.; Pulcini, C.; Barbois, S.; Botelho-Nevers, E. Vaccine hesitancy among general practitioners: Evaluation and comparison of their immunisation practice for themselves, their patients and their children. Eur. J. Clin. Microbiol. Infect. Dis. 2016, 35, 1837–1843. [Google Scholar] [CrossRef] [PubMed]
- Agrinier, N.; Le Maréchal, M.; Fressard, L.; Verger, P.; Pulcini, C. Discrepancies between general practitioners’ vaccination recommendations for their patients and practices for their children. Clin. Microbiol. Infect. 2017, 23, 311–317. [Google Scholar] [CrossRef] [Green Version]
- Paterson, P.; Meurice, F.; Stanberry, L.R.; Glismann, S.; Rosenthal, S.L.; Larson, H.J. Vaccine hesitancy and healthcare providers. Vaccine 2016, 34, 6700–6706. [Google Scholar] [CrossRef] [Green Version]
- Verger, P.; Scronias, D.; Dauby, N.; Adedzi, K.A.; Gobert, C.; Bergeat, M.; Gagneur, A.; Dubé, E. Attitudes of healthcare workers towards COVID-19 vaccination: A survey in France and French-speaking parts of Belgium and Canada, 2020. Eurosurveillance 2021, 26, 2002047. [Google Scholar] [CrossRef] [PubMed]
- Likert, R. A Technique for the Measurement of Attitudes. Arch. Psychol. 1932, 22, 55. [Google Scholar]
- Plotkin, S.A.; Offit, P.A.; DeStefano, F.; Larson, H.J.; Arora, N.K.; Zuber, P.L.; Fombonne, E.; Sejvar, J.; Lambert, P.H.; Hviid, A.; et al. The science of vaccine safety: Summary of meeting at Wellcome Trust. Vaccine 2020, 38, 1869–1880. [Google Scholar] [CrossRef]
- Sarkanen, T.O.; Alakuijala, A.P.; Dauvilliers, Y.; Partinen, M. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. Sleep Med. Rev. 2018, 38, 177–186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arias, L.M.; Sanz, R.; Sainz-Gil, M.; Treceño, C.; Carvajal, A. Guillain-Barré syndrome and influenza vaccines: A meta-analysis. Vaccine 2015, 33, 3773–3778. [Google Scholar] [CrossRef]
- Salmon, D.A.; Dudley, M.Z.; Glanz, J.M.; Omer, S.B. Vaccine Hesitancy. Am. J. Prev. Med. 2015, 49, S391–S398. [Google Scholar] [CrossRef]
- Karlsson, L.C.; Lewandowsky, S.; Antfolk, J.; Salo, P.; Lindfelt, M.; Oksanen, T.; Kivimäki, M.; Soveri, A. The association between vaccination confidence, vaccination behavior, and willingness to recommend vaccines among Finnish healthcare workers. PLoS ONE 2019, 14, e0224330. [Google Scholar] [CrossRef] [PubMed]
- Kernéis, S.; Jacquet, C.; Bannay, A.; May, T.; Launay, O.; Verger, P.; Pulcini, C.; Abgueguen, P.; Ansart, S.; Bani-Sadr, F.; et al. Vaccine Education of Medical Students: A Nationwide Cross-sectional Survey. Am. J. Prev. Med. 2017, 53, e97–e104. [Google Scholar] [CrossRef] [PubMed]
- Conseil Supérieur de la Santé (CSS). Vaccination Contre Le Méningocoque—Avis N°9485; Conseil Supérieur de la Santé: Brussel, Belgium, 2019. [Google Scholar]
- Le Marechal, M.; Fressard, L.; Agrinier, N.; Verger, P.; Pulcini, C. General practitioners’ perceptions of vaccination controversies: A French nationwide cross-sectional study. Clin. Microbiol. Infect. 2018, 24, 858–864. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ramière, C.; Roche, L.; Scholtès, C.; Iwaz, J.; Saison, J.; Ecochard, R.; André, P. Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994. Clin. Microbiol. Infect. 2016, 22, 889.e1–889.e7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smith, P.J.; Kennedy, A.M.; Wooten, K.; Gust, D.A.; Pickering, L.K. Association Between Health Care Providers’ Influence on Parents Who Have Concerns About Vaccine Safety and Vaccination Coverage. Pediatrics 2006, 118, e1287–e1292. [Google Scholar] [CrossRef] [PubMed]
- Larson, H.J.; Cooper, L.Z.; Eskola, J.; Katz, S.L.; Ratzan, S. Addressing the vaccine confidence gap. Lancet 2011, 378, 526–535. [Google Scholar] [CrossRef]
- McRee, A.-L.; Gilkey, M.B.; Dempsey, A.F. HPV Vaccine Hesitancy: Findings from a Statewide Survey of Health Care Providers. J. Pediatr. Health Care 2014, 28, 541–549. [Google Scholar] [CrossRef] [Green Version]
Characteristics | Numbers (%) |
---|---|
Personal Characteristics | |
Sex | |
Men | 103/251 (41.0%) |
Women | 148/251 (59.0%) |
Age | |
25–34 | 85/251 (33.8%) |
35–49 | 52/251 (20.7%) |
50–64 | 82/251 (32.7%) |
65 and above | 32/251 (12.8%) |
Office location (2 missing values) | |
Brussels-Regio | 56/249 (22.5%) |
Walloon Brabant | 52/249 (20.9%) |
Hainaut | 79/249 (31.7%) |
Namur Province | 24/249 (9.6%) |
Liège Province | 30/249 (12%) |
Luxembourg Province | 8/249 (3.2%) |
Professional Characteristics | |
Type of practice | |
Solo | 104/251 (41.4%) |
Association | 104/251 (41.4%) |
Medical Center | 47/251 (18.3%) |
Alternative medicine offered | |
Yes | 46/251 (18.3%) |
No | 205/251 (81.7%) |
Participation in immunization training course in 2019 | |
Yes | 194/251 (77.3%) |
No | 57/251 (22.7%) |
Feels a need for training on vaccination | |
Yes | 133/251 (53%) |
No | 118/251 (47%) |
Vaccination Experience | |
Experience with a selected vaccine-preventable disease in the past 5 years (measles, complicated influenza, chronic hepatitis B (HBV), bacterial meningitis, or cervical cancer) | |
Yes | 222/251 (88.4%) |
No | 29/251 (11.6%) |
Had a patient with severe disease potentially related to vaccination | |
Yes | 27/251 (10.8%) |
No | 224/251 (89.2%) |
Opinion about Vaccination | |
Favorable to vaccination in general | |
Very Favorable | 231/251 (92%) |
Rather Favorable | 20/251 (8%) |
Rather Not Favorable | 0/251 (0%) |
Not Favorable | 0/251 (0%) |
Think patients must be convinced to get vaccinated even if they are hesitant | |
Yes | 115/251 (45.8%) |
Rather Yes | 129/251 (51.4%) |
Rather Not | 7/251 (2.8%) |
No | 0/251 (0.0%) |
Personal Vaccination History | |
Influenza vaccination, season 2018–2019 | |
Yes | 198/251 (78.9%) |
No | 53/251 (21.1%) |
Last diphtheria–tetanus–pertussis dose/booster | |
<10 years | 218/251 (86.8%) |
10–20 years | 26/251 (10.4%) |
>20 years | 6/251 (2.34%) |
Unknown | 1/251 (0.4%) |
Hepatitis B vaccination | |
Yes, 3 or more doses | 226/251 (90%) |
Yes, less than 3 doses | 10/251 (4%) |
Never or do not remember | 10/251 (4%) |
Not concerned | 5/251 (2%) |
Vaccine Hesitancy | ||||
---|---|---|---|---|
None to Low N = 124 | Moderate to High N = 127 | All N = 251 | p-Value (Fisher) | |
Perceived link between vaccines and potential severe side-effects (somewhat likely, very likely) | ||||
Influenza and Guillain-Barré | 18/124 (14.5%) | 26/127 (20.5%) | 17.5% | 0.25 |
Hepatitis B and multiple sclerosis | 1/124 (0.8%) | 8/127 (6.3%) | 3.6% | 0.04 |
Human papillomavirus (HPV) and multiple sclerosis | 0/124 (0.0%) | 6/127 (4.7%) | 2.4% | 0.03 |
Aluminum and Alzheimer’s disease | 3/124 (2.4%) | 5/127 (3.9%) | 3.2% | 0.72 |
Pandemrix and narcolepsy | 13/124 (10.5%) | 5/127 (3.9%) | 7.2% | 0.052 |
Adjuvants and long-term complications | 2/124 (1.6%) | 15/127 (11.8%) | 6.8% | 0.002 |
Perceived usefulness of vaccines (mostly agree, totally agree) | ||||
Some vaccines recommended by authorities are not helpful | 6/124 (4.8%) | 15/127 (11.8%) | 8.4% | 0.07 |
Children are vaccinated against too many diseases | 6/124 (4.8%) | 7/127 (5.5%) | 5.2% | 0.87 |
Referral frequency (often, always) | ||||
Measles–mumps–rubella (MMR) in unimmunized adolescents and young adults | 120/124 (96.8%) | 92/127 (72.4%) | 84.5% | <0.0001 |
Meningococcus C at 13–15 months | 110/124 (88.7%) | 65/127 (51.2%) | 69.7% | <0.0001 |
Catch-up for meningococcus C | 80/124 (64.5%) | 2/127 (1.6%) | 32.7% | <0.0001 |
Human Papillomavirus (HPV) in girls 11–14 years old | 123/124 (99.2%) | 115/127 (90.6%) | 94.8% | <0.01 |
Catch-up hepatitis B in adolescents | 115/124 (92.7%) | 27/127 (21.3%) | 56.6% | <0.0001 |
Flu in people with diabetes <65 years | 123/124 (99.2%) | 106/127 (83.5%) | 91.2% | <0.001 |
Characteristics (n = 251) | VH None to Low n (%) | VH Moderate to High n (%) | OR (CI 95%) | p-Value | AOR (CI 95%) | p-Value |
---|---|---|---|---|---|---|
Personal Characteristics | ||||||
Sex | ||||||
Men | 52/124 (41.94%) | 51/127 (40.2%) | 1.08 | 0.80 | ||
Women | 72/124 (58.06%) | 76/127 (59.8%) | (0.63–1.84) | |||
Age | ||||||
≥50 years’ old | 68/124 (54.84%) | 46/127 (36.2%) | 2.14 | 1.76 | ||
<50 years’ old | 56/124 (45.16%) | 81/127 (63.8%) | (1.25–3.66) | <0.01 | (1.02–3.03) | 0.04 |
At least one child | ||||||
Yes | 92/124 (74.19%) | 57/127 (46%) | 3.53 | 3.11 | ||
No | 32/124 (25.81%) | 70/127 (56%) | (2.00–6.25) | <0.001 | (1.79–5.40) | <0.001 |
Professional Characteristics | ||||||
Offer alternative medicine | ||||||
Yes | 22/124 (17.74%) | 24/127 (18.9%) | 0.93 | |||
No | 102/124 (82.26%) | 103/127 (81.1%) | (0.46–1.85) | 0.87 | ||
Immunization training course <5 years | ||||||
Yes | 104/124 (83.87%) | 90/127 (70.9%) | 2.14 | 1.92 | ||
No | 20/124 (16.13%) | 37/127 (29.1%) | (1.11–4.17) | 0.02 | (1.00–3.70) | 0.051 |
Vaccination Experience | ||||||
Experience with a selected vaccine-preventable disease (measles, complicated influenza, chronic hepatitis B (HBV), bacterial meningitis or cervical cancer) | ||||||
Yes | 118/124 (95.16%) | 104/127 (81.9%) | 4.35 | 3.23 | ||
No | 6/124 (4.84%) | 23/127 (18.1%) | (1.63–13.50) | 0.001 | (1.24–8.42) | 0.02 |
Experience with a serious health problem potentially related to the vaccine | ||||||
Yes | 9/124 (7.26%) | 18/127 (14.2%) | 0.47 | |||
No | 115/124 (92.74%) | 109/127 (85.8%) | (0.18–1.17) | 0.1 | ||
Personal Vaccination History | ||||||
Influenza vaccination season 2018–2019 | ||||||
Yes | 98/124 (79.03%) | 100/127 (78.7%) | 1.02 | |||
No | 26/124 (20.97%) | 27/127 (21.3%) | (0.53–1.96) | 1 | ||
Last DTP dose | ||||||
<10 years | 109/124 (87.90%) | 109/127 (85.8%) | 1.20 | |||
≥10 years or does not remember | 15/124 (12.10%) | 18/127 (14.2%) | (0.54–2.70) | 0.71 | ||
Hepatitis B vaccination | ||||||
Yes, 3 doses or more | 111/124 (89.52%) | 115/127 (90.6%) | ||||
Less than 3 or does not remember | 10/124 (8.06%) | 10/127 (7.9%) | ||||
Not concerned | 3/124 (2.42%) | 2/127 (1.5%) | 0.94 |
Decision for Their Children | |||
---|---|---|---|
Frequency of Recommendation to Their Patients | All Are Vaccinated | None or Some Are Vaccinated | Total |
Measles–mumps–rubella (for adolescents and young adults) | |||
Always | 101/147 (68.7%) | 2/2 (100%) | 103/149 (69.1%) |
Not always | 46/147 (31.3%) | 0/2 (0%) | 46/149 (30.9%) |
Meningococcus C at 15 months * | |||
Always | 84/139 (60,43%) | 1/8 (12.5%) | 85/147 (57.8%) |
Not always | 55/139 (39,57%) | 7/8 (87.5%) | 62/147 (42.2%) |
Human papillomavirus (HPV) in girls 11–14 years old ** | |||
Always | 59/77 (76.6%) | 0/6 (0%) | 59/83 (71.1%) |
Not always | 18/77 (23.4%) | 6/6 (100%) | 24/83 (28.9%) |
Catch-up hepatitis B vaccine | |||
Always | 54/144 (37.5%) | 0/5 (0%) | 54/149 (36.2%) |
Not always | 90/144 (62.5%) | 5/5 (100%) | 95/149 (63.8%) |
Vaccine Hesitancy (%) | |||
---|---|---|---|
Belgian GP (Present Study) | French GP (from the Study by Verger et al. [11]) | ||
Moderate to High N = 127 | Moderate N = 166 | High N = 56 | |
Perceived link between vaccines and potential severe side-effects (somewhat likely, very likely) | |||
Influenza and Guillain-Barré | 20.5 | 29.9 | 66.2 |
Hepatitis B and multiple sclerosis | 6.3 | 30.3 | 82.8 |
Human papillomavirus (HPV) and multiple sclerosis | 4.7 | 15.2 | 70.9 |
Aluminum and Alzheimer’s disease | 3.9 | 28.8 | 46.4 |
Pandemrix and narcolepsy | 3.9 | 27.4 | 50.5 |
Adjuvants and long-term complications | 11.8 | 48.2 | 88.5 |
Perceived usefulness of vaccines (mostly agree, totally agree) | |||
Some vaccines recommended by authorities are not helpful | 11.8 | 40.1 | 60.4 |
Children are vaccinated against too many diseases | 5.5 | 36.5 | 62.4 |
Referral frequency (often, always) | |||
Measles–mumps–rubella (MMR) in unimmunized adolescents and young adults | 72.4 | 55.8 | 52.6 |
Meningococcus C at 15 months | 51.2 | 52.8 | 30.6 |
Catch-up for meningococcus C | 1.6 | 36.2 | 20.8 |
Human papillomavirus (HPV) in girls 11–14 years old | 90.6 | 46.9 | 24.5 |
Catch-up hepatitis B in adolescents | 21.3 | 41.5 | 29.7 |
Flu in people with diabetes <65 years | 83.5 | 69.9 | 47.5 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gobert, C.; Semaille, P.; Van der Schueren, T.; Verger, P.; Dauby, N. Prevalence and Determinants of Vaccine Hesitancy and Vaccines Recommendation Discrepancies among General Practitioners in French-Speaking Parts of Belgium. Vaccines 2021, 9, 771. https://doi.org/10.3390/vaccines9070771
Gobert C, Semaille P, Van der Schueren T, Verger P, Dauby N. Prevalence and Determinants of Vaccine Hesitancy and Vaccines Recommendation Discrepancies among General Practitioners in French-Speaking Parts of Belgium. Vaccines. 2021; 9(7):771. https://doi.org/10.3390/vaccines9070771
Chicago/Turabian StyleGobert, Cathy, Pascal Semaille, Thierry Van der Schueren, Pierre Verger, and Nicolas Dauby. 2021. "Prevalence and Determinants of Vaccine Hesitancy and Vaccines Recommendation Discrepancies among General Practitioners in French-Speaking Parts of Belgium" Vaccines 9, no. 7: 771. https://doi.org/10.3390/vaccines9070771
APA StyleGobert, C., Semaille, P., Van der Schueren, T., Verger, P., & Dauby, N. (2021). Prevalence and Determinants of Vaccine Hesitancy and Vaccines Recommendation Discrepancies among General Practitioners in French-Speaking Parts of Belgium. Vaccines, 9(7), 771. https://doi.org/10.3390/vaccines9070771